Amarantus Bioscience Holdings Stock Probability of Future Pink Sheet Price Finishing Over 1.0E-4
| AMBS Stock | USD 0.0001 0.00 0.00% |
Amarantus |
Amarantus Bioscience Target Price Odds to finish over 1.0E-4
The tendency of Amarantus Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 62.91 |
Based on a normal probability distribution, the odds of Amarantus Bioscience to move above the current price in 90 days from now is about 62.91 (This Amarantus Bioscience Holdings probability density function shows the probability of Amarantus Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 9.02 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Amarantus Bioscience will likely underperform. In addition to that Amarantus Bioscience Holdings has an alpha of 21.0777, implying that it can generate a 21.08 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Amarantus Bioscience Price Density |
| Price |
Predictive Modules for Amarantus Bioscience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Amarantus Bioscience. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Amarantus Bioscience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Amarantus Bioscience is not an exception. The market had few large corrections towards the Amarantus Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Amarantus Bioscience Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Amarantus Bioscience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 21.08 | |
β | Beta against Dow Jones | 9.02 | |
σ | Overall volatility | 0.0002 | |
Ir | Information ratio | 0.17 |
Amarantus Bioscience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Amarantus Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Amarantus Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Amarantus Bioscience is way too risky over 90 days horizon | |
| Amarantus Bioscience has some characteristics of a very speculative penny stock | |
| Amarantus Bioscience appears to be risky and price may revert if volatility continues | |
| Amarantus Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| Amarantus Bioscience Holdings currently holds 20.72 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Amarantus Bioscience has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amarantus Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Amarantus Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amarantus Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amarantus to invest in growth at high rates of return. When we think about Amarantus Bioscience's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (10.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Amarantus Bioscience Holdings currently holds about 178 in cash with (1.8 M) of positive cash flow from operations. |
Amarantus Bioscience Technical Analysis
Amarantus Bioscience's future price can be derived by breaking down and analyzing its technical indicators over time. Amarantus Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Amarantus Bioscience Holdings. In general, you should focus on analyzing Amarantus Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Amarantus Bioscience Predictive Forecast Models
Amarantus Bioscience's time-series forecasting models is one of many Amarantus Bioscience's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Amarantus Bioscience's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Amarantus Bioscience
Checking the ongoing alerts about Amarantus Bioscience for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Amarantus Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Amarantus Bioscience is way too risky over 90 days horizon | |
| Amarantus Bioscience has some characteristics of a very speculative penny stock | |
| Amarantus Bioscience appears to be risky and price may revert if volatility continues | |
| Amarantus Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| Amarantus Bioscience Holdings currently holds 20.72 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Amarantus Bioscience has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amarantus Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Amarantus Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amarantus Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amarantus to invest in growth at high rates of return. When we think about Amarantus Bioscience's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (10.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Amarantus Bioscience Holdings currently holds about 178 in cash with (1.8 M) of positive cash flow from operations. |
Additional Tools for Amarantus Pink Sheet Analysis
When running Amarantus Bioscience's price analysis, check to measure Amarantus Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amarantus Bioscience is operating at the current time. Most of Amarantus Bioscience's value examination focuses on studying past and present price action to predict the probability of Amarantus Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amarantus Bioscience's price. Additionally, you may evaluate how the addition of Amarantus Bioscience to your portfolios can decrease your overall portfolio volatility.